Articles Celgene’s new CEO weighs in to drug pricing debate Celgene's new CEO Mark Alles discusses pricing and M&A, criticises Valeant's approach. Richard Staines reports.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.